Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
9.97
+0.34 (3.53%)
At close: Jun 6, 2025, 4:00 PM
9.97
0.00 (0.00%)
After-hours: Jun 6, 2025, 7:00 PM EDT
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $28.00M in the quarter ending March 31, 2025, a decrease of -80.69%. This brings the company's revenue in the last twelve months to $141.00M, down -40.51% year-over-year. In the year 2024, Arcus Biosciences had annual revenue of $258.00M with 120.51% growth.
Revenue (ttm)
$141.00M
Revenue Growth
-40.51%
P/S Ratio
6.36
Revenue / Employee
$224,880
Employees
627
Market Cap
1.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RCUS News
- 5 days ago - Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response - Business Wire
- 10 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 4 weeks ago - Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 6 weeks ago - Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting - Business Wire
- 6 weeks ago - Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
- 2 months ago - Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
- 3 months ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire